Read by QxMD icon Read


Hakeam A Hakeam, Zainab Al Duhailib, Nawal Salahuddin, Tarek Amin
The aim of this prospective, randomized study was to compare the effects of tigecycline and imipenem-cilastatin on fibrinogen levels in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Patients were empirically randomized to receive tigecycline or imipenem-cilastatin. Fibrinogen levels were measured in both patient groups on days 1, 3, 5 and 8 of antibiotic therapy and 3 days after antibiotic therapy completion. Twenty patients received tigecycline and 22 patients received imipenem-cilastatin ...
March 22, 2018: Journal of Chemotherapy
Taoufik Ladhari, Konrad Szafnicki
Usual therapies against malignant tumors, such as surgery, chemotherapy, radiation, is severe and when repeated their efficiency may decrease because tumorous cells may become resistant. Contrarily, hyperthermia has been known for some time as an effective auxiliary treatment, which can be applied repeatedly. In some cases of abdominal carcinomatosis, particularly those of digestive origin, HIPEC is considered as an promising therapeutic option. Chemotherapy and hyperthermia are combined via the perfusion of the abdominal cavity with hot fluids containing chemotherapeutic agents, thus, augmenting the influence of appropriate chemotherapeutic agents with heat...
April 2018: 3 Biotech
F Roviello
No abstract text is available yet for this article.
March 2018: European Journal of Cancer
Marco Ceresoli, Apollonia Verrengia, Giulia Montori, Luisa Busci, Federico Coccolini, Luca Ansaloni, Luigi Frigerio
OBJECTIVE: Hyperthermic intraperitoneal chemotherapy (HIPEC) has been proposed as a treatment in ovarian cancer. A recently published RCT demonstrated that HIPEC prolongs disease-free survival (DFS) and overall survival (OS) in ovarian cancer. The aim of the study was to investigate oncologic results of cytoreductive surgery+HIPEC compared with cytoreductive surgery alone in advanced primary ovarian cancer with a particular attention to the pattern of recurrence. METHODS: This is a retrospective case control study with a propensity score (PS) matching of the patients...
March 12, 2018: Journal of Gynecologic Oncology
Geert A Simkens, Koen P Rovers, Thijs R van Oudheusden, Simon W Nienhuijs, Harm J Rutten, Ignace H de Hingh
Complications after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) result in impaired short- and long-term outcomes. However, financial consequences of complications after CRS and HIPEC in a European health care setting are unknown. This study aims to assess the consequences of complications on hospital costs after CRS and HIPEC.In this prospective observational cohort study, patients with colorectal peritoneal metastases treated with CRS and HIPEC were included. Financial information was collected according to the Dutch manual for costs analyses...
March 2018: Medicine (Baltimore)
Thomas S Zajonz, Michael Sander, Winfried Padberg, Andreas Hecker, Ruediger Hörbelt, Christian Koch, Emmanuel Schneck
Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) poses a widely used and accepted treatment option for patients with peritoneal carcinomatosis of gastrointestinal tumors. In contrast to the well-described risks and complications of intravenous cytostatic drugs, literature offers only scarce information of serious complications following HIPEC. To our knowledge no other description of rapid progressive pulmonary hypertension (PH) and consecutive respiratory failure following HIPEC have been described in current literature...
March 2018: Annals of Medicine and Surgery
Federica Bruno, Dario Baratti, Antonia Martinetti, Daniele Morelli, Elisa Sottotetti, Chiara Bonini, Marcello Guaglio, Shigeki Kusamura, Marcello Deraco
BACKGROUND: The differential diagnosis between diffuse malignant peritoneal mesothelioma (DMPM) and other peritoneal surface malignancies (PSM) is still challenging. Serum mesothelin and osteopontin are increasingly used as markers of pleural mesothelioma, but their role in DMPM is unclear. We assessed the diagnostic and prognostic values of mesothelin, osteopontin, CEA, CA19.9, CA125, and CA15.3 in DMPM patients. METHODS: Markers were dosed before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) by enzyme-linked immunosorbent assay (ELISA) in 30 DMPM patients and 14 controls with other PSMs...
February 17, 2018: European Journal of Surgical Oncology
Mark B Bignell, Akash M Mehta, Sue Alves, Kandiah Chandrakumaran, Sanjeev P Dayal, Faheez Mohamed, Tom D Cecil, Brendan J Moran
AIM: Ovarian metastases from gastrointestinal tract malignancy have been considered an ominous finding with poor prognosis. The aim of this project was to determine the impact on survival, and potential cure, when cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are combined to treat peritoneal malignancy in women with Krukenberg tumours. METHOD: Retrospective analysis of prospectively collected data between January 2010 and July 2015...
March 4, 2018: Colorectal Disease: the Official Journal of the Association of Coloproctology of Great Britain and Ireland
Yang Liu, Yutaka Yonemura, Edward A Levine, Olivier Glehen, Diane Goere, Dominique Elias, David L Morris, Paul H Sugarbaker, Jean J Tuech, Peter Cashin, John D Spiliotis, Ignace de Hingh, Wim Ceelen, Joel M Baumgartner, Pompiliu Piso, Kanji Katayama, Marcello Deraco, Shigeki Kusamura, Marc Pocard, François Quenet, Sachio Fushita
BACKGROUND: The multi-institutional registry in this study evaluated the outcome after cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases (PM) from small bowel adenocarcinoma (SBA). METHODS: A multi-institutional data registry including 152 patients with PM from SBA was established. The primary end point was overall survival (OS) after CRS plus HIPEC. RESULTS: Between 1989 and 2016, 152 patients from 21 institutions received a treatment of CRS plus HIPEC...
February 26, 2018: Annals of Surgical Oncology
Carlos Gustavo Trujillo, Cristina Domínguez, Daniela Robledo, Juan Ignacio Caicedo, Alejandra Bravo-Balado, Juan Guillermo Cataño, Natalia Cortés, Lina Parra, Wilson Riaño, Eduardo Londoño-Schimmer, Jorge Otero, Gabriel Herrera, Fernando Arias, Mauricio Plata
BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is associated with significant manipulation of the urinary tract (UT). We aim to describe the urological events and their management in patients who underwent CRS-HIPEC. METHODS: Clinical records of patients who underwent treatment between 2007 and 2015 were reviewed. Urological events and their multidisciplinary management were analyzed. Descriptive statistics were calculated...
February 23, 2018: Acta Chirurgica Belgica
D Di Miceli, C Cina, C Fiorillo, G B Doglietto, S Alfieri
OBJECTIVE: Integration of different therapeutic strategies in cancer surgery in the last years has led from treating primary lesions to the surgical treatment of metastases. The purpose of this paper is to report a single Italian center experience of treatment of peritoneal carcinosis of the abdominopelvic malignancies. PATIENTS AND METHODS: 103 HIPEC procedures were performed in 17 years on 94 selected patients affected by abdominopelvic cancer. The PCI score was calculated at laparotomy...
February 2018: European Review for Medical and Pharmacological Sciences
A Arjona-Sánchez, P Barrios, E Boldo-Roda, B Camps, J Carrasco-Campos, V Concepción Martín, A García-Fadrique, A Gutiérrez-Calvo, R Morales, G Ortega-Pérez, E Pérez-Viejo, A Prada-Villaverde, J Torres-Melero, E Vicente, P Villarejo-Campos, J M Sánchez-Hidalgo, A Casado-Adam, Ruben García-Martin, Manuel Medina, T Caro, C Villar, Enrique Aranda, M T Cano-Osuna, C Díaz-López, E Torres-Tordera, F J Briceño-Delgado, S Rufián-Peña
BACKGROUND: Local relapse and peritoneal carcinomatosis (PC) for pT4 colon cancer is estimated in 15,6% and 36,7% for 12 months and 36 months from surgical resection respectively, achieving a 5 years overall survival of 6%. There are promising results using prophylactic HIPEC in this group of patients, and it is estimated that up to 26% of all T4 colon cancer could benefit from this treatment with a minimal morbidity. Adjuvant HIPEC is effective to avoid the possibility of peritoneal seeding after surgical resection...
February 13, 2018: BMC Cancer
Syeda Nadia Shah Gilani, Akash Mehta, Alfonso Garcia-Fadrique, Babatunde Rowaiye, Veronika Jenei, Sanjeev Dayal, Kandiah Chandrakumaran, Norman Carr, Faheez Mohamed, Tom Cecil, Brendan Moran
BACKGROUND: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) benefits selected patients with peritoneal mesothelioma. We present the outcomes of this treatment strategy in a UK peritoneal malignancy national referral centre. METHODS: Observational retrospective analysis of data prospectively collected in a dedicated peritoneal malignancy database between March 1998 and January 2016. RESULTS: Of 1586 patients treated for peritoneal malignancy, 76 (4...
February 12, 2018: International Journal of Hyperthermia
Yael Dreznik, Aviad Hoffman, Tamar Hamburger, Almog Ben-Yaacov, Yossi Dux, Harel Jacoby, Yaniv Berger, Aviram Nissan, Mordechai Gutman
BACKGROUND: Cytoreductive surgery and Hyperthermic intra-peritoneal chemotherapy (CRS/HIPEC) for peritoneal surface malignancies is associated with high morbidity. The increased numbers of patients undergoing CRS/HIPEC in recent years mandates risk analysis and quality assurance. However, only scarce data exist regarding causative parameters for readmission. The aim of this study was to assess readmission rates and risk factors associated with readmission. METHODS: A retrospective-cohort study including patients from two high-volume centers who underwent CRS/HIPEC surgery between the years 2007-2016 was performed...
February 8, 2018: Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
Hakeam A Hakeam, Amal Arab, Ayman Azzam, Zyad Alyahya, Abdelmoneim M Eldali, Tarek Amin
INTRODUCTION: Cytopenia after hyperthermic intraperitoneal chemotherapy (HIPEC) with cytoreductive surgery (CRS) has been reported in non-comparative studies with various chemotherapeutic regimens. This study compared the incidence of leukopenia and thrombocytopenia in patients who underwent CRS/HIPEC and received melphalan or cisplatin plus mitomycin-c (CIS + MMC). METHODS: This retrospective study included patients who underwent CRS/HIPEC at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia from March 2011 to March 2017 and received melphalan 60 mg/m 2 or CIS 100 mg/m 2 combined with MMC 30 mg/m 2 ...
February 10, 2018: Cancer Chemotherapy and Pharmacology
Paul H Sugarbaker
BACKGROUND: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) may be of greatest benefit if all visible evidence of disease is resected. In some male patients the peritoneal metastases within the pelvis are invasive into the seminal vesicles and complete cytoreduction requires resection of these structures. PATIENTS AND METHODS: From a prospective database of colorectal and appendiceal cancer patients who had CT evidence of seminal vesicle involvement and then had cytoreduction including resection of the seminal vesicles were reviewed...
January 12, 2018: European Journal of Surgical Oncology
H Richard Alexander, Claire Yue Li, Timothy J Kennedy
PURPOSE: Diffuse malignant peritoneal mesothelioma (MPM) is a rare and ultimately fatal cancer that was first described just over a century ago. It is a diffuse malignancy arising from the mesothelial lining of the peritoneum; morbidity and mortality from MPM is due to its propensity to progress locoregionally within the abdominal cavity. METHODS: The purpose of this article is to review the current state-of-the-science related to the diagnosis, staging, and treatment of MPM...
February 8, 2018: Annals of Surgical Oncology
J-B Delhorme, F Severac, G Averous, O Glehen, G Passot, N Bakrin, F Marchal, M Pocard, R Lo Dico, C Eveno, S Carrere, O Sgarbura, F Quenet, G Ferron, D Goéré, C Brigand
BACKGROUND: The prognostic value of the primary neoplasm responsible for pseudomyxoma peritonei (PMP) remains poorly studied. The aim of this study was to determine the prognosis for patients with extra-appendicular PMP (EA-PMP) treated optimally with complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: All patients treated for PMP with CCRS and HIPEC between 1994 and 2016 were selected retrospectively from a French multicentre database...
February 7, 2018: British Journal of Surgery
Ángel Serrano Del Moral, Estibalitz Pérez Viejo, Israel Manzanedo Romero, Gil Rodríguez Caravaca, Fernando Pereira Pérez
INTRODUCTION: To analyze the impact of systematic second-look surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) performed 1 year after resection of the primary tumor, in asymptomatic patients at high risk of developing peritoneal carcinomatosis (PC). METHODS: Between 2012-2016, 33 patients without any sign of peritoneal recurrence on imaging studies were prospectively included in the study and underwent second-look surgery aimed at treating limited PC earlier and were prospectively recorded...
February 2, 2018: Cirugía Española
Manuela Robella, Marco Vaira, Alice Borsano, Michele DE Simone
BACKGROUND: Actual cure rate and patterns of recurrence after cytoreductive surgery (CRS) associated to hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with colorectal peritoneal carcinomatosis (PC) are not yet well explored. Moreover, the selection policy to this resource-consuming treatment is still a matter of debate. METHODS: From a dataset of 400 CRS+HIPEC performed between October 1996 and December 2015, we selected 54 consecutive patients with colorectal PC...
February 1, 2018: Minerva Chirurgica
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"